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Summary 
Catecholamines and GABA are neurotransmitters involved in the regu- 
lation of release of pro-opiomelanocortin (POMC) derived peptides 
from the neurointermediate lobe of Xenopu8 laevis. The present study 
concerns the relation of these neurotransmitters to the adenylate 
cyclase system of the melanotrope cell. During in vitro incubation 
of isolated melanotrope cells it was found that dopamine, adrenaline 
and LY 171555 induced inhibition of forskolin-stimulated cAMP pro- 
duction sad concomitantly inhibited MSH release. 
Activation of the GABAb receptors by baclofen also induced inhibit- 
ion of cAMP production and aMSH secretion. Activation of the GABAa 
receptors evoked stimualtion of cAMP production, while aMSH release 
was slightly inhibited, indicating that the GABAa mechanism may 
prove to be complex. A dual regulation through two subtypes of this 
receptor might be involved, one stimulating release through the 
adenylate cyclase system, while the other would inhibit secretion. 
The secretory cells of the pars intermedia of the pituitary gland synthesize the 
bioactive peptide Melanophore-Stimulating Hormone (aMSH). In amphibians, these 
melanotrope cells are involved in the neuroendocrine reflex regulating pigment 
dispersion in dermal melanophores (background adaptation). Animals placed on a 
black background release mMSH which, by stimulating dispersion of black pigment 
within the melanophores, leads to a darkening of the animals (I, 2). Recent 
studies indicate that hypothalamic regulation of the secretory activity of 
amphibian melanotropes, which involves stimulatory and inhibitory mechanisms, is 
exerted through a number of factors, both classical neurotransmitters (3, 4, 5, 
6, 7) and neuropeptides (8, 9, 10, 11). Many of these factors function through 
a direct action on the melanotrope cell itself (12), indicating that this cell 
is a major center of neuroendocrine integration. An understanding of the intra- 
cellular mechanisms of this integration may help in establishing the physiolog- 
ical significance of the general phenomenon of multiple factors regulating 
pituitary cell function. 
It has been shown that regulation of eMSH release from the pars intermedia of 
the aquatic toad, Xenopu8 L~evis, involves both a dopaminergic and a GABAergic 
system. Dopamine induces an inhibition of MSH secretion (13, 14, 15). Studies 
with isolated melanotrope cells of fenopu8 (cell suspensions) have established 
that this effect is exerted through direct action of the secretagogue on the 
melanotrope (12). Using specific receptor agonists and antagonists it has been 
shown that, in Xenopus, dopamine functions through a receptor which has similar 
but not identical characteristics to the dopamine D 2 receptor of mammalian 
melanotropes (16). The pars intermedia of Xenopu8 L~evi8 possesses a rich net- 
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work of GABAergic nerve terminals, and the neurotransmitter GABA is very potent 
in inhibiting secretion of MSH from the intermediate lobe of this amphibian 
(7). Receptor characterization studies show that both GABAa and GABAb receptors 
are present and that activation of either receptor type leads to an inhibition 
of MSH secretion (17). GABAa and GABAb receptor agonists inhibit secretion from 
the isolated Xenopu~ melanotrope, indicating that the melanotrope itself pos- 
sesses both GABA receptor-types (12). 
Earlier studies have reported the involvement of cyclic-AMP (cAMP) in the 
release process of the Xenopu8 MSH cells (6, lh, ~8, 19). The purpose of the 
present investigation was I) to establish if dopamine inhibits MSH release from 
the Xenopus melanotrope through an inhibition of the adenylate cyclase system 
and 2) to determine the effect of specific GABAa and GABAb receptor agonists on 
the production of cyclic-AMP by these cells. For this purpose isolated melano- 
tropes of Xenopu8 laeu~8 were used. cAMP levels were measured using a cyclic-AMP 
protein binding assay, and the secretion of MSH from the melanotropes was moni- 
tored by radioimmunoassay. 
Materials and Methods 
Animals 
Xenopus laevis were bred and reared in our aquatic facility. Prior to the exper- 
iments the animals were kept for at least two weeks on a black background under 
constant illumination at 22C. 
Preparation of cell suspensions 
Preparation of cell suspensions and tests concerning cell viability have been 
published earlier (12). Neurointermediate lobes were dissected in incubation 
medium (IM) containing 112 mM NaCl, 2 mM KCI, 2 mM CaC~.2  }{20 , 2 mg/ml glucose, 
15 mM Hepes pH 7.38. The medium was preaerated with carbogen. The tissue was 
subsequently transferred to 1.5 ml IM to which was added 3 mg/ml bovine serum 
albumin (BSA, Sigma fraction V), 1 mg/ml collagenase (Sigma) and 1.25 mg/ml dis- 
pase (grade II lyophilisat, Boehringer) and incubated for 1 h in a shaking wat- 
erbath at 22C. After centrifugation (I0 min, 200 g, 22C) the pellet was careful- 
ly suspended in 1.5 ml Ca-free medium to which 3 mg/ml BSA and 0.4 mg/ml EDTA 
were added. The suspension was centrifuged, resuspended in 1.5 ml Ca-free medium 
with 3 mg/ml BSA and 1.25 mg/ml dispase and incubated for 30 min at 22C with 
shaking. Tissue fragments were then allowed to settle and the supernatant con- 
taining melanotropes in suspension (fraction I) was saved. The fragments were 
rinsed and retreated with Ca-free medium containing BSA and dispase, and centri- 
fuged for 3 min at 200 g over a nylon filter (pore size 0.15 ~m). The collected 
cell suspension (fraction 2) was combined with fraction 1 and centrifuged (i0 
min 200 g). The pellet was rinsed and resuspended in medium containing 3 mg/ml 
BSA, 0.8 mg/ml EDTA. Finally it was centrifuged and suspended in incubation 
medium with 0.3 mg/ml BSA. All glassware was siliconized. 
Superfusion of isolated melanotropes 
Cells were suspended in a small volume of incubation medium and loaded in a 50 
N1 superfusion chamber with a millipore 0.45 Nm filter (type HA) at the outlet 
to support a layer of biogel P2 (Biorad). After loading, the chamber was filled 
with biogel. Medium was pumped with a peristaltic pump at a rate of 1.5 ml/h and 
7.5 min fractions were collected in i00 ~i ice-cold 0.i N HCI. Fractions were 
stored at -20C before submission to radioimmunoassay. After an equilibration 
period of approximately 1 h the effect of cAMP was investigated by giving 15 min 
pulses of medium containing 6 mM 8-Br-cAMP (Sigma). 
Radioimmunoassay for cMSH 
The C-terminal directed antiserum was produced and characterized by Vaudry et al 
(20). This antiserum has equal reactivity to ~MSH and des-acetyl-~MSH. Bound 
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and unbound MSH were separated by precipitation with polyethyleneglycol (final 
concentration 7.5%). Sensitivity threshold of the assay is 5 pg. 
Static incubations of melanotrope cells 
Cells were washed in IM with 3 mg/ml BSA and 10-4M of Isobutylmethyl Xanthine 
(IBHX, Sigma). After centrifugation these cells were subsequently incubated for 
45 min in 250 ~I of IM containing 0.3 mg/ml BSA, 2 mg/ml glucose, 10-~M IBMX, 
and 30 BM of forskolin at 22C. Cells were then centrifuged for I0 min at 200 g 
and 200 B1 supernatant was taken for radioimmunoassay of =MSH. To the cells 450 
~i of 6% TCA was added (end concentration of TCA ± 5%) and the proteins were 
allowed to precipitate for 15 min on ice. The mixture was centrifuged at 2000 g 
and the supernatant was kept at -20C for cAMP binding assay. 
To investigate the effect of neurotransmitters on the intracellular cAMP produc- 
tion, experimental incubations were performed in presence of 10-bH dopamine 
(Sigma), 10-bM dopamine + 30 ~M pertussis toxin (P.H.L. Service, Centre for 
applied Microbiol. and Research, Salisbury); 5x10-YM LY171555 (Lilly Co.); 10-6M 
adrenaline; 10-bM baclofen (a kind gift of Ciba Geigy) or 10-4H isoguvacine 
(Cambridge Research Chemicals). 
cAMP binding assay 
cAMP binding assay was based on the method according to Kempen et al. (21). cAMP 
binding protein, prepared according to Brown eta] .  (22), was kindly provided by 
Dr P.H.G.M. Willems. TCA was eliminated from the supernatant by repeated 
extraction with 5 ml of water-saturated diethylether. Subsequently 2 pmol of 
[3H]cAMP (48 Ci/mmol Amersham) was added. The extract was purified over a 
Dowex-50WX8 column (3 cm x 0.5 cm) which was equilibrated in 0 .01N HCI and 
eluted with destilled water. ~ne cAMP containing fraction was dried overnight 
under N 2 at 30C. 350 B1 of cAMP binding protein, dissolved in medium containing 
50 mM Tris (pH 7.4), 8 mM theophylline, 5 mH EDTA, 1.7 mM MgS0h.7H20 , 0.93 mg/ml 
dithiothreitol (D.T.T.), was added to the dry sample which was then left for i h 
on ice. Of this sample 50 gl was taken to measure the recovery of c-AMP for 
each column. To the remaining 300 BI, 1 ml of charcoal 0.01 g/ml in 50 mM Tris 
pH 7.4, 0.2 g/ml BSA was added. After mixing and centrifugation (5 min at 3000 
g) 500 ~i of the supernatant was added to 4 ml of Scintillator 199 (Packard) and 
the radioactivity was determined in a liquid scintillation analyzer. For each 
assay a standard curve was made by adding [3H]cAMP to known amounts of cAMP 
which were then treated identical to the tissue samples, to subsequently estab- 
lish recovery and % binding. 
Results 
Effect of 8-Br-cAMP on NSH release 
Administration of cAMP during in vitro superfusion of isolated intermediate lobe 
cells resulted in a significant increase of MSH secretion from these cells to 
233 ± 63% (n=4) (fig. I). After 7.5 min a small increase was visible which only 
reached a maximum after 30 min. 
Measurement of cAMP production 
Preliminary experiments showed that basal levels of cAMP in isolated melano- 
tropes of Xenopus laevis were under the limit of detection of the binding assay. 
Production of cAMP during a one hour in vitro incubation of 2 pars intermedia 
equivalents of cells in the presence of IBMX also remained under the detection 
limit. Stimulation of cAHP synthesis by forskolin resulted in a dose- and time- 
dependent increase of cAHP production and therefore forskolin was used in all 
subsequent incubations to bring cAMP production within detection limits of the 
assay. A 45 min in vitro incubation in 30 ~H forskolin was selected as the stan- 
dard incubation protocol. During this period an average of 51.1 ± 5.3 pmol 
cAMP/intermediate lobe was measured (n=29). 
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Fig. 1. Stimulation of eMSH secretion 
by 8-Br-cAMP during in vitro superfu- 
sion of intermediate lobe cells of 
Xenopus Zaevis. cAMP (6 mM) was admin- 
istered during 15 min of the superfu- 
sion period as indicated in the figure. 
7.5 Min fractions were collected. 
Figure represents the average of 4 
individual superfusion experiments. 
100% Values were calculated from the 
average secretion during fractions I-4 
and were respectively 96 pg, 204 pg, 
304 pg, 196 Pg/7.5 min fraction. 
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Effects of dopamine, LY177555 and adrenaline on cAMP production and release of 
aMSH 
Incubation of intermediate lobe ceils in the presence of dopamine (10-5M) 
resulted in a significant decrease of the forskolin stimulated production of 
cAMP and also the release of MSH from these cells (table I, fig. 2). Pertussis 
toxin (500 ng/ml), an inhibitor of the inhibitory G protein of the adenylate 
cyclase system, significantly reduced the dopamine induced inhibition of adeny- 
late cyclase activity and could also completely reverse the dopamine induced 
inhibition of aMSH release (table i). The dopamine D 2 receptor agonist LY171555 
(5xl0-?M), like dopamine, decreased both cAMP production and aMSH release. 
Adrenaline ( i0-~) also inhibited both cAMP production and release of aMSH. 
TABLE I. 
Inhibition of cAMP production and MSH release by dopamine, LY171555, and adrena- 
line in intermediate lobe cells of Xenopus laevis. 
cAMP % a MSH % 
Forskolin 
Forskolin + dopamine (10-5M) 
Forskolin + dopamine (10-5M) + 
pertussis toxin (500 ng/ml) 
Forskolin + LY171555 (5.10-~M) 
Forskolin + adrenaline (10-6M) 
i00 i00 
42.6 ± 3.2 (n=12) 53.7 ± 5.5 (n=10) 
65.6 + 6.3 (n= 5) 
35.3 + 4.7 (n = 2) 
66.3 + 6.7 (n = 4) 
98.3 + 4.4 (n = 4) 
64.4 + 5.1 (n= 2) 
54.1 + 3.6 (n = 4) 
cAMP production and MSH release were measured after a 45-min incubation of 
intermediate lobe cells in the presence of forskolin (30 NM) and IBMX (10-5M). 
Average absolute levels of control incubations in this medium were resp. 51 pmol 
cAMP/intermediate lobe equivalent and 3734 pg MSH/intermediate lobe equivalent. 
cAMP production and MSH release in the presence of dopamine, dopamine + pertus- 
sis toxin, LY171555 or adrenaline are expressed as a percentage of their control 
values. The cAMP values of the experimental groups were all significantly 
reduced in comparison to the control incubations (p < 0.05). Moreover, the incu- 
bation with dopamine and pertussis toxin was determined to be significantly dif- 
ferent from the value obtained after incubation in dopamine alone (Mann-Whitney 
U-test). The MSH values obtained after incubation in dopamine, LY171555 and 
adrenaline were significantly different from their control values. 
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Effects of GABAb and GABAa receptor agonists on cAMP production and release of 
aMSU 
Baclofen (10-5 M), a specific agonist of GABAb receptors induced significant 
inhibition of cAMP production and aMSH secretion. Isoguvacine (IO-~M), a spe- 
cific agonist of GABAa receptors, gave a significant increase in cAMP produc- 
tion. During this incubation MSH release was slightly but not significantly 
reduced (fig. 2). 
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Discussion 
From previous reports, the exact role of adenylate cyclase activity in regula- 
tion of MSH secretion from the pars intermedia would seem unclear. Cyclic-AMP 
analogues have been shown to stimulate (14, 15, 18), to inhibit (19), or to have 
no effect on MSH release (23). In a recent study this issue was examined (6). We 
used neurointermediate lobes in superfusion, which has an advantage over the 
more commonly used static incubation methods in that the basal secretion pro- 
vides an internal control. It was shown that pulses of 8-Br-cAMP stimulate MSH 
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release from lobes of white- but not from lobes of black-background adapted ani- 
mals. The present results show that melanotrope cells, isolated from neuroin- 
termediate lobes of black-background adapted animals, are sensitive to cAMP, 
which caused an enhanced release of MSH. The reason for a different response 
from whole lobes or isolated cells is not clear. Possibly, the prolonged in 
vftro inhibition of release due to the isolation of cells in Ca-free medium was 
sufficient to lower intracellular levels of c_AMP, thus propelling the cells 
towards a physiological condition comparable to that in white-background adapted 
animals. 
From the measurement of cAMP production following incubation of isolated melano- 
tropes in dopamine-containing medium we conclude that dopamine induced inhib- 
ition of MSH release is intracellularly mediated through inhibition of cAMP pro- 
duction. This conclusion is based on the observations that l) cAMP is a 
stimulatory factor for MSH release and 2) dopamine inhibits both cAMP production 
and release of MSH. In a recent study Loh et al. came to a different conclusion 
concerning the mechanism of dopamine induced inhibition of MSH secretion (23). 
This study involved incubation of whole neurointermediate lobes of black- 
background adapted animals. Preincubation of 12-14 days was necessary to allow 
most of the neural lobe tissue to degenerate, as this latter tissue would mask 
the cAMP signal from the intermediate lobe. They too found that dopamine, dur- 
ing a 60-min in vitro incubation, inhibits cAMP production but concluded that 
this neurotransmitter acts via adenylate cyclase not for the inhibition of MSH 
release but for the direct inhibition of POMC biosynthesis. This conclusion is 
based firstly, on the finding that cAMP itself had no effect on release of MSH 
from freshly dissected lobes of black background adapted animals, a phenomenon 
that we have already commented upon, and secondly, on the finding that a pro- 
longed incubation in the presence of dopamine inhibits POMC synthesis. Concern- 
ing this latter observation, in view of the rapid secretory response of the 
intermediate lobe cells to dopamine, and the prolonged treatment required for 
this neurotransmitter to inhibit POMC biosynthesis, it is, in our view, not 
clear to what extent inhibition of POMC synthesis is directly regulated by dopa- 
mine. 
Dopamine receptors in the mammalian intermediate lobe have been classified as D 2 
dopamine receptors (24, 25, 26). Mammalian intermediate lobe tissue is in fact 
often used as a model system for studies on dopamine D2 receptors and on the 
intracellular effects that are generated after stimulation of these receptors 
(25, 26). These mammalian Dp receptors intracellularly evoke inhibition of cAMP 
production via the inhibitory subunit of the adenylate cyclase system. For the 
Xenopus 7aevis neurointermediate lobe it was recently established that the 
receptors for dopamine show many characteristics of the mammalian D2 receptors 
but, unlike the latter, they do not respond to the specific D 2 antagonist 
YMO9151-2 and are very sensitive to other catecholamines (16). Moreover, it was 
found that dopamine, theD 2 receptor agonist LY171555, and adrenaline, although 
all being blocked by the D 2 antagonist sulpiride, did not have an identical pro- 
file of antagonists. Therefore, the presence of two catecholaminergic receptors 
or receptor sites was postulated. The present study shows that activation of 
Xenopus catecholamine receptors by dopamine, LY171555 or adrenaline evokes a 
similar intracellular effect, namely inhibition of cAMP production. The apparent 
inhibitory effect of pertussis toxin (26, 27) on dopamine induced inhibition of 
cAMP production and MSH release would indicate that, as in the mammal, the N i 
unit of the adenylate cyclase system is involved in the melanotrope cell 
response to dopamine. 
Concerning GABAergic mechanisms regulating MSH secretion in Xenopus, we have 
previously shown that both GABAa and GABAb receptors are present and that the 
GABAb mechanism is predominant during in vitro treatment with GABA (17). In the 
pars intermedia of the rat (28, 29), the pig (30), and the amphibian Rana ridi- 
bunda (31), GABA has been shown to cause a short stimulation in vitro, followed 
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by a sustained inhibition. In all cases  it is believed that this sustained 
inhibition is at least partly caused by activation of GABAb receptors (28, 29, 
30, 31, 32). Our present results show that GABAb receptors, like the catechola- 
mine receptors, function through inhibition of adenylate cyclase. While there 
are reports that GABAb receptors of the central nervous system of the rat func- 
tion through inhibition of the adenylate cyclase system (33, 34, 35), the intra- 
cellular mechanism associated with this receptor in inhibiting MSH secretion in 
either the rat or the amphibian has never been addressed. 
The involvement of GABAa receptors in regulating MSH secretion has been reported 
not only for Xenopus but also for rat (28, 29, 32, 37), pig (30) and Rana ridi- 
bunda (31). There appear to be species differences with regard to the tissue 
response to activation of this receptor type. In all species, the transient 
stimulation of MSH release functions through a GABAa receptor mechanism. While 
for the rat and pig there is strong evidence for an important role of GABAb 
receptors in mediating a sustained inhibition of secretion, for Rana the GABAa 
receptor is thought to be dominant over the GABAb receptor. In all cases it is 
believed that stimulation of release is induced through increased membrane 
permeability to the C1- ion. In Xemopus we have previously reported a predomi- 
nant inhibition of MSH secretion through GABA b receptors (17). We suggested that 
the CI- electrochemical equilibrium point of the intermediate lobe cells of 
Xenopus differs from that in the above species and thus opening of CI- channels 
in Xenopus would cause hyperpolarization. Our present results concerning activa- 
tion of GABAa receptors through administration of the specific agonist isoguva- 
cine (37), sho~ a very interesting phenomenon. Isoguvacine is very potent in 
inhibiting MSH secretion from whole lobes and from melanotrope cells in suspen- 
sion. We now show that the isoguvacine-induced inhibition of MSff secretion in 
the presence of forskolin and IBMX is much lower than expected when compared to 
the results obtained with dopamine and baclofen. Moreover, cAMP production was 
stimulated by isoguvacine, and thus one would have expected stimulation of MSH 
release. This discrepancy might indicate that activation of GABAa receptors has 
a dual effect on the melanotrope cells, namely a stimulatory effect through ade- 
nylate cyclase and an inhibitory effect through another intracellular mechanism, 
possibly the CI- channel. In our earlier study we showed that GABAa agonists 
could induce a slight stimulation of MSH secretion at the lowest concentration 
of their dose-response curve (17), suggesting that in Xenopus intermediate 
lobes, the stimulatory effect is masked by the predominant inhibitory mechanism. 
The apparent stimulation at low concentration could be explained when the dual 
effect is exerted through two sites of the GABAa receptor, or through two dif- 
ferent subtypes of the GABAa receptor as has been proposed by Anderson and Mit- 
chel for rat lactotropes (38, 39). In our in vitro system adenylate-cyclase- 
linked stimulation would be revealed only at low concentrations due to a 
slightly higher sensitivity of this receptor-site or subtype to isoguvacine. The 
present incubations, however, were performed in a forskolin containing medium. 
Forskolin is known not only to stimulate the adenylate cyclase but also to 
potentiate the effect of factors that stimulate the adenylate cyclase activity 
(40). Potentiation of a GABAa site working through adenylate cyclase might 
explain the lower inhibition of MSH release by isoguvacine. 
In conclusion, the present findings reveal that in the melanotrope cells of the 
Xenopus pars intermedia at least two distinct intracellular pathways might be 
involved to generate the final release response. Catecholamines will inhibit the 
adenylate cyclase through receptors which probably activate the inhibitory subu- 
nit. Activation of GABAb receptors will also inhibit intracellular cyclic AMP 
production. For GABAa receptors we propose that they can induce a dual effect, 
possibly through two subtypes or sites of this receptor, one of which activates 
the adenylate cyclase system. In view of this latter finding it should now be 
established whether the inhibition of MSH release in Xenopus 7aevis, through 
activation of GABAa receptors, is caused by a hyperpolarizing shift of the mem- 
brane potential through the opening of chloride channels. 
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